表紙
市場調查報告書

胞外體治療藥的全球市場:產業趨勢與未來預測

Global Exosome Therapeutic Market - Industry Trends and Forecast to 2026

出版商 Data Bridge Market Research Private Limited 商品編碼 919199
出版日期 內容資訊 英文 245 Pages
商品交期: 最快1-2個工作天內
價格
胞外體治療藥的全球市場:產業趨勢與未來預測 Global Exosome Therapeutic Market - Industry Trends and Forecast to 2026
出版日期: 2019年11月01日內容資訊: 英文 245 Pages
簡介

本報告提供全球外吐小體治療藥的市場相關分析,市場基本結構和促進、阻礙因素,整體市場規模趨勢預測,各類型、各原料、各治療法、搬運物質、各用途、各給藥途徑、各終端用戶、各地區的詳細趨勢,市場競爭環境,主要企業簡介等調查。

第1章 簡介

第2章 市場區隔

第3章 市場概要

  • 推動市場要素
  • 阻礙市場要素
  • 市場機會
  • 課題

第4章 摘要整理

第5章 重要考察

第6章 產品平台

第7章 全球胞外體治療藥市場:各類型

  • 概要
  • 混合胞外體
  • 天然胞外體
    • 自製胞外體
    • 外陰性胞外體

第8章 全球胞外體治療藥市場:各原料

  • 概要
  • 間質幹細胞 (MSC)
  • 樹突狀細胞
  • 血液
    • B型細胞
    • 其他
  • 體液
    • 滑液 (關節液)
    • 羊水
    • 精液
    • 其他
  • 唾液
  • 尿
  • 其他

第9章 全球胞外體治療藥市場:各治療法

  • 概要
  • 化療
  • 免疫療法
  • 基因治療

第10章 全球胞外體治療藥市場:各搬運物質

  • 概要
  • 生物高分子
    • 核酸
    • 蛋白質
  • 小分子

第11章 全球胞外體治療藥市場:各用途

  • 概要
  • 腫瘤
    • 非小細胞肺癌 (NSCLC)
    • 乳癌
    • 胃癌
    • 頭部、頸部癌症
    • 其他
  • 心臟疾病
  • 代謝異常
  • 神經疾病
    • 帕金森氏症
    • 阿茲海默症
    • 其他
  • 血液疾病
  • 婦女病
  • 發炎性疾病
  • 器官移植
  • 其他

第12章 全球胞外體治療藥市場:各給藥途徑 (ROA)

  • 概要
  • 非口服給藥
  • 口服給藥

第13章 全球胞外體治療藥市場:各終端用戶

  • 概要
  • 醫院
  • 研究、教育設施
  • 診斷中心

第14章 全球胞外體治療藥市場:各地區

  • 概要
  • 北美 (美國,墨西哥)
  • 亞太地區 (韓國,香港,澳洲)
  • 南美 (阿根廷,哥倫比亞,秘魯,智利,委內瑞拉,巴拿馬,多明尼加共和國,薩爾瓦多,巴拉圭,哥斯大黎加,波多黎各,尼加拉瓜,烏拉圭)
  • 土耳其

第15章 全球胞外體治療藥市場:企業環境

  • 概要
  • 各企業佔有率分析:全球整體

第16章 企業簡介

  • STEM CELLS GROUP
    • 企業概要
    • 市場收益額分析
    • 產品/開發平台、組合
    • 近幾年的主要趨勢
    • 企業佔有率分析等
  • EXOCOBIO
  • AEGLE THERPEUTICS
  • AVALON GLOBOCARE CORP.
  • BOEHRINGER INGELHEIM INTERNATIONAL GMBH
  • CAPRICOR THERAPEUTICS
  • CODIAK BIOSCIENCES
  • CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.
  • EXOPHARM
  • EVOX THERAPEUTICS
  • JAZZ PHARMACEUTICALS, INC.
  • RENEURON GROUP PLC
  • UNITED THERAPEUTICS CORPORATION

第17章 調查問卷

第18章 相關分析

目錄

Global exosome therapeutic market is projected to register a healthy CAGR of 21.9% in the forecast period 2019 to 2026. The new market report contains data for historic year 2017, the base year of calculation is 2018 and the forecast period is 2019 to 2026.

Market Segmentation

Global Exosome Therapeutic Market By Type (Natural Exosomes, Hybrid Exosomes), Source (Dendritic Cells, Mesenchymal Stem Cells, Blood, Milk, Body Fluids, Saliva, Urine Others), Therapy (Immunotherapy, Gene Therapy, Chemotherapy), Transporting Capacity (Bio Macromolecules, Small Molecules), Application (Oncology, Neurology, Metabolic Disorders, Cardiac Disorders, Blood Disorders, Inflammatory Disorders, Gynecology Disorders, Organ Transplantation, Others), Route of Administration (Oral, Parenteral), End User (Hospitals, Diagnostic Centers, Research & Academic Institutes), Geography (North America, Europe, Asia-Pacific and Latin America)

Some of the major factors contributing to the growth of the market:

  • Increasing prevalence of Lyme disease, chronic inflammation, autoimmune disease and other chronic degenerative diseases
  • Increasing demand for anti-aging therapy's

Key Market Players

The key market players for global exosome therapeutic market are listed below:

  • evox THERAPEUTICS
  • EXOCOBIO
  • Exopharm
  • AEGLE Therapeutics
  • United Therapeutics Corporation
  • Codiak BioSciences
  • Jazz Pharmaceuticals, Inc.
  • Boehringer Ingelheim International GmbH
  • ReNeuron Group plc
  • Capricor Therapeutics
  • Avalon Globocare Corp.
  • CREATIVE MEDICAL TECHNOLOGY HOLDINGS INC.
  • Stem Cells Group

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION
  • 1.3 OVERVIEW OF GLOBAL EXOSOME THERAPEUTIC MARKET
  • 1.4 LIMITATIONS
  • 1.5 MARKETS COVERED

2 MARKET SEGMENTATION

  • 2.1 MARKETS COVERED
  • 2.2 GEOGRAPHICAL SCOPE
  • 2.3 YEARS CONSIDERED FOR THE STUDY
  • 2.4 CURRENCY AND PRICING
  • 2.5 DBMR TRIPOD DATA VALIDATION MODEL
  • 2.6 MULTIVARIATE MODELLING
  • 2.7 PRODUCTS LIFELINE CURVE
  • 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
  • 2.9 SECONDARY SOURCES
  • 2.10 ASSUMPTIONS

3 MARKET OVERVIEW

  • 3.1 DRIVERS
    • 3.1.1 INCREASING PREVALENCE OF LYME DISEASE, CHRONIC INFLAMMATION, AUTOIMMUNE DISEASE AND OTHER CHRONIC DEGENERATIVE DISEASES
    • 3.1.2 INCREASING DEMAND FOR ANTI-AGING THERAPY'S
  • 3.2 RESTRAINT
    • 3.2.1 UNMET MEDICAL NEEDS
  • 3.3 OPPORTUNITIES
    • 3.3.1 PROGRESSING THERAPEUTIC VALUE OF EXOSOME
    • 3.3.2 AVAILABILITY OF VARIOUS EXOSOME ISOLATION AND PURIFICATION TECHNIQUES
    • 3.3.3 TECHNOLOGICAL ADVANCEMENTS IN EXOSOME
    • 3.3.4 STRATEGIC RESEARCH INITIATIVES BY MARKET PLAYERS
    • 3.3.5 RISING HEALTHCARE INFRASTRUCTURE
  • 3.4 CHALLENGE
    • 3.4.1 LACK OF SKILLED PROFESSIONAL'S REQUIRED FOR THE ISOLATION OF EXOSOME

4 EXECUTIVE SUMMARY

5 PREMIUM INSIGHTS

6 PIPELINE

7 GLOBAL EXOSOME THERAPEUTIC MARKET, BY TYPE

  • 7.1 OVERVIEW
  • 7.2 HYBRID EXOSOMES
  • 7.3 NATURAL EXOSOMES
    • 7.3.1 AUTOLOGOUS EXOSOMES
    • 7.3.2 EXOGENOUS EXOSOMES

8 GLOBAL EXOSOME THERAPEUTIC MARKET, BY SOURCE

  • 8.1 OVERVIEW
  • 8.2 MESENCHYMAL STEM CELLS
  • 8.3 DENDRITIC CELLS
  • 8.4 BLOOD
    • 8.4.1 B LYMPHOCYTES
    • 8.4.2 OTHERS
  • 8.5 BODY FLUIDS
    • 8.5.1 SYNOVIAL FLUID
    • 8.5.2 AMNIOTIC FLUID
    • 8.5.3 SEMEN
    • 8.5.4 OTHERS
  • 8.6 MILK
  • 8.7 SALIVA
  • 8.8 URINE
  • 8.9 OTHERS

9 GLOBAL EXOSOME THERAPEUTIC MARKET, BY THERAPY

  • 9.1 OVERVIEW
  • 9.2 CHEMOTHERAPY
  • 9.3 IMMUNOTHERAPY
  • 9.4 GENE THERAPY

10 GLOBAL EXOSOME THERAPEUTIC MARKET, BY TRANSPORTING CAPACITY

  • 10.1 OVERVIEW
  • 10.2 BIO MACROMOLECULES
    • 10.2.1 NUCLEIC ACIDS
    • 10.2.2 PEPTIDES
    • 10.2.3 PROTEINS

  • 10.3 SMALL MOLECULES

11 GLOBAL EXOSOME THERAPEUTIC MARKET, BY APPLICATION

  • 11.1 OVERVIEW
  • 11.2 ONCOLOGY
    • 11.2.1 NON-SMALL CELL LUNG CANCER
    • 11.2.2 BREAST CANCER
    • 11.2.3 GASTRIC CANCER
    • 11.2.4 HEAD AND NECK CANCER
    • 11.2.5 OTHERS
  • 11.3 CARDIAC DISORDERS
  • 11.4 METABOLIC DISORDERS
  • 11.5 NEUROLOGY
    • 11.5.1 PARKINSON'S DISEASE
    • 11.5.2 ALZHEIMER'S DISEASE
    • 11.5.3 OTHERS
  • 11.6 BLOOD DISORDERS
  • 11.7 GYNECOLOGY DISORDERS
  • 11.8 INFLAMMATORY DISORDERS
  • 11.9 ORGAN TRANSPLANTATION
  • 11.10 OTHERS

12 GLOBAL EXOSOME THERAPEUTIC MARKET, BY ROUTE OF ADMINISTRATION

  • 12.1 OVERVIEW
  • 12.2 PARENTERAL
  • 12.3 ORAL

13 GLOBAL EXOSOME THERAPEUTIC MARKET, BY END USER

  • 13.1 OVERVIEW
  • 13.2 HOSPITALS
  • 13.3 RESEARCH & ACADEMIC INSTITUTES
  • 13.4 DIAGNOSTIC CENTERS

14 GLOBAL EXOSOME THERAPEUTIC MARKET, BY GEOGRAPHY

  • 14.1 OVERVIEW
  • 14.2 NORTH AMERICA
    • 14.2.1 U.S.
    • 14.2.2 MEXICO

  • 14.3 ASIA-PACIFIC
    • 14.3.1 SOUTH KOREA
    • 14.3.2 HONG KONG
    • 14.3.3 AUSTRALIA
  • 14.4 LATIN AMERICA
    • 14.4.1 ARGENTINA
    • 14.4.2 COLOMBIA
    • 14.4.3 PERU
    • 14.4.4 CHILE
    • 14.4.5 ECUADOR
    • 14.4.6 VENEZUELA
    • 14.4.7 PANAMA
    • 14.4.8 DOMINICAN REPUBLIC
    • 14.4.9 EL SALVADOR
    • 14.4.10 PARAGUAY
    • 14.4.11 COSTA RICA
    • 14.4.12 PUERTO RICO
    • 14.4.13 NICARAGUA
    • 14.4.14 URUGUAY
  • 14.5 TURKEY

15 GLOBAL EXOSOME THERAPEUTIC MARKET, COMPANY LANDSCAPE

  • 15.1 COMPANY SHARE ANALYSIS: GLOBAL

16 COMPANY PROFILE

  • 16.1 STEM CELLS GROUP
    • 16.1.1 COMPANY SNAPSHOT
    • 16.1.2 PRODUCT PORTFOLIO
    • 16.1.3 RECENT DEVELOPMENT
  • 16.2 EXOCOBIO
    • 16.2.1 COMPANY SNAPSHOT
    • 16.2.2 PRODUCT PORTFOLIO
    • 16.2.3 RECENT DEVELOPMENT
  • 16.3 AEGLE THERPEUTICS
    • 16.3.1 COMPANY SNAPSHOT
    • 16.3.2 PIPELINE PORTFOLIO
  • 16.4 AVALON GLOBOCARE CORP.
    • 16.4.1 COMPANY SNAPSHOT
    • 16.4.2 REVENUE ANALYSIS
    • 16.4.3 PIPELINE PORTFOLIO
    • 16.4.4 RECENT DEVELOPMENT
  • 16.5 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    • 16.5.1 COMPANY SNAPSHOT
    • 16.5.2 REVENUE ANALYSIS
    • 16.5.3 PRODUCT PORTFOLIO
    • 16.5.4 RECENT DEVELOPMENT
  • 16.6 CAPRICOR THERAPEUTICS
    • 16.6.1 COMPANY SNAPSHOT
    • 16.6.2 PRODUCT PORTFOLIO
    • 16.6.3 RECENT DEVELOPMENTS
  • 16.7 CODIAK BIOSCIENCES
    • 16.7.1 COMPANY SNAPSHOT
    • 16.7.2 PIPELINE PORTFOLIO
    • 16.7.3 RECENT DEVELOPMENTS
  • 16.8 CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.
    • 16.8.1 COMPANY SNAPSHOT
    • 16.8.2 REVENUE ANALYSIS
    • 16.8.3 PIPELINE PORTFOLIO
    • 16.8.4 RECENT DEVELOPMENT
  • 16.9 EXOPHARM
    • 16.9.1 COMPANY SNAPSHOT
    • 16.9.2 REVENUE ANALYSIS
    • 16.9.3 PIPELINE PORTFOLIO
    • 16.9.4 RECENT DEVELOPMENT
  • 16.10 EVOX THERAPEUTICS
    • 16.10.1 COMPANY SNAPSHOT
    • 16.10.2 PIPELINE PORTFOLIO
    • 16.10.3 RECENT DEVELOPMENTS
  • 16.11 JAZZ PHARMACEUTICALS, INC.
    • 16.11.1 COMPANY SNAPSHOT
    • 16.11.2 REVENUE ANALYSIS
    • 16.11.3 PRODUCT PORTFOLIO
    • 16.11.4 RECENT DEVELOPMENT
  • 16.12 RENEURON GROUP PLC
    • 16.12.1 COMPANY SNAPSHOT
    • 16.12.2 REVENUE ANALYSIS
    • 16.12.3 PRODUCT PORTFOLIO
    • 16.12.4 RECENT DEVELOPMENT

  • 16.13 UNITED THERAPEUTICS CORPORATION
    • 16.13.1 COMPANY SNAPSHOT
    • 16.13.2 REVENUE ANALYSIS
    • 16.13.3 PRODUCT PORTFOLIO
    • 16.13.4 RECENT DEVELOPMENT

17 QUESTIONNAIRE

18 RELATED REPORTS

LIST OF TABLES

  • TABLE 1 EXOSOMES USED AS DRUG/GENE DELIVERY CARRIERS.
  • TABLE 2 COMPARISON OF CONVENTIONAL AND MICROFLUIDICS-BASEDEXOSOME ISOLATION TECHNIQUES
  • TABLE 3 STRATEGIC RESEARCH INITIATIVES BY MARKET PLAYERS
  • TABLE 4 HEALTHCARE EXPENDITURE IN ASIA-PACIFIC
  • TABLE 5 GLOBAL EXOSOME THERAPEUTIC MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 6 GLOBAL HYBRID EXOSOMES IN EXOSOME THERAPEUTIC MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 7 GLOBAL NATURAL EXOSOMES IN EXOSOME THERAPEUTIC MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 8 GLOBAL NATURAL EXOSOMES IN EXOSOME THERAPEUTIC MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 9 GLOBAL EXOSOME THERAPEUTIC MARKET, BY SOURCE, 2017-2026 (USD MILLION)
  • TABLE 10 GLOBAL MESENCHYMAL STEM CELLS IN EXOSOME THERAPEUTIC MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 11 GLOBAL DENDRITIC CELLS IN EXOSOME THERAPEUTIC MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 12 GLOBAL BLOOD IN EXOSOME THERAPEUTIC MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 13 GLOBAL BLOOD IN EXOSOME THERAPEUTIC MARKET, BY SOURCE, 2017-2026 (USD MILLION)
  • TABLE 14 GLOBAL BODY FLUIDS IN EXOSOME THERAPEUTIC MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 15 GLOBAL BODY FLUIDS IN EXOSOME THERAPEUTIC MARKET, BY SOURCE, 2017-2026 (USD MILLION)
  • TABLE 16 GLOBAL MILK IN EXOSOME THERAPEUTIC MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 17 GLOBAL SALIVA IN EXOSOME THERAPEUTIC MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 18 GLOBAL URINE IN EXOSOME THERAPEUTIC MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 19 GLOBAL OTHERS IN EXOSOME THERAPEUTIC MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 20 GLOBAL EXOSOME THERAPEUTIC MARKET, BY THERAPY, 2017-2026 (USD MILLION)
  • TABLE 21 GLOBAL CHEMOTHERAPY IN EXOSOME THERAPEUTIC MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 22 GLOBAL IMMUNOTHERAPY IN EXOSOME THERAPEUTIC MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 23 GLOBAL GENE THERAPY IN EXOSOME THERAPEUTIC MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 24 GLOBAL EXOSOME THERAPEUTIC MARKET, BY TRANSPORTING CAPACITY, 2017-2026 (USD MILLION)
  • TABLE 25 GLOBAL BIO MACROMOLECULES IN EXOSOME THERAPEUTIC MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 26 GLOBAL BIO MACROMOLECULES IN EXOSOME THERAPEUTIC MARKET, BY SOURCE, 2017-2026 (USD MILLION)
  • TABLE 27 GLOBAL SMALL MOLECULES IN EXOSOME THERAPEUTIC MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 28 GLOBAL EXOSOME THERAPEUTIC MARKET, BY APPLICATION, 2017-2026 (USD MILLION)
  • TABLE 29 GLOBAL ONCOLOGY IN EXOSOME THERAPEUTIC MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 30 GLOBAL ONCOLOGY IN EXOSOME THERAPEUTIC MARKET, BY APPLICATION, 2017-2026 (USD MILLION)
  • TABLE 31 GLOBAL CARDIAC DISORDERS IN EXOSOME THERAPEUTIC MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 32 GLOBAL METABOLIC DISORDERS IN EXOSOME THERAPEUTIC MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 33 GLOBAL NEUROLOGY IN EXOSOME THERAPEUTIC MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 34 GLOBAL NEUROLOGY IN EXOSOME THERAPEUTIC MARKET, BY APPLICATION, 2017-2026 (USD MILLION)
  • TABLE 35 GLOBAL BLOOD DISORDERS IN EXOSOME THERAPEUTIC MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 36 GLOBAL GYNECOLOGY DISORDERS IN EXOSOME THERAPEUTIC MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 37 GLOBAL INFLAMMATORY DISORDERS IN EXOSOME THERAPEUTIC MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 38 GLOBAL ORGAN TRANSPLANTATION IN EXOSOME THERAPEUTIC MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 39 GLOBAL OTHERS IN EXOSOME THERAPEUTIC MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 40 GLOBAL EXOSOME THERAPEUTIC MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)
  • TABLE 41 GLOBAL PARENTERAL IN EXOSOME THERAPEUTIC MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 42 GLOBAL ORAL IN EXOSOME THERAPEUTIC MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 43 GLOBAL EXOSOME THERAPEUTIC MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 44 GLOBAL HOSPITALS IN EXOSOME THERAPEUTIC MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 45 GLOBAL RESEARCH & ACADEMIC INSTITUTES IN EXOSOME THERAPEUTIC MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 46 GLOBAL DIAGNOSTIC CENTERS IN EXOSOME THERAPEUTIC MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 47 GLOBAL EXOSOME THERAPEUTIC MARKET, BY REGION, 2017-2026 (USD MILLION)
  • TABLE 48 NORTH AMERICA EXOSOME THERAPEUTIC MARKET, BY COUNTRY 2017-2026 (USD MILLION)
  • TABLE 49 NORTH AMERICA EXOSOME THERAPEUTIC MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 50 NORTH AMERICA NATURAL EXOSOMES IN EXOSOME THERAPEUTIC MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 51 NORTH AMERICA EXOSOME THERAPEUTIC MARKET, BY SOURCE, 2017-2026 (USD MILLION)
  • TABLE 52 NORTH AMERICA BLOOD IN EXOSOME THERAPEUTIC MARKET, BY SOURCE, 2017-2026 (USD MILLION)
  • TABLE 53 NORTH AMERICA BODY FLUIDS IN EXOSOME THERAPEUTIC MARKET, BY SOURCE, 2017-2026 (USD MILLION)
  • TABLE 54 NORTH AMERICA EXOSOME THERAPEUTIC MARKET, BY THERAPY, 2017-2026 (USD MILLION)
  • TABLE 55 NORTH AMERICA EXOSOME THERAPEUTIC MARKET, BY TRANSPORTING CAPACITY, 2017-2026 (USD MILLION)
  • TABLE 56 NORTH AMERICA BIO MACROMOLECULES IN EXOSOME THERAPEUTIC MARKET, BY TRANSPORTING CAPACITY, 2017-2026 (USD MILLION)
  • TABLE 57 NORTH AMERICA EXOSOME THERAPEUTIC MARKET, BY APPLICATION, 2017-2026 (USD MILLION)
  • TABLE 58 NORTH AMERICA ONCOLOGY IN EXOSOME THERAPEUTIC MARKET, BY APPLICATION, 2017-2026 (USD MILLION)
  • TABLE 59 NORTH AMERICA NEUROLOGY IN EXOSOME THERAPEUTIC MARKET, BY APPLICATION, 2017-2026 (USD MILLION)
  • TABLE 60 NORTH AMERICA EXOSOME THERAPEUTIC MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)
  • TABLE 61 NORTH AMERICA EXOSOME THERAPEUTIC MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 62 U.S. EXOSOME THERAPEUTIC MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 63 U.S. NATURAL EXOSOMES IN EXOSOME THERAPEUTIC MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 64 U.S. EXOSOME THERAPEUTIC MARKET, BY SOURCE, 2017-2026 (USD MILLION)
  • TABLE 65 U.S. BLOOD IN EXOSOME THERAPEUTIC MARKET, BY SOURCE, 2017-2026 (USD MILLION)
  • TABLE 66 U.S. BODY FLUIDS IN EXOSOME THERAPEUTIC MARKET, BY SOURCE, 2017-2026 (USD MILLION)
  • TABLE 67 U.S. EXOSOME THERAPEUTIC MARKET, BY THERAPY, 2017-2026 (USD MILLION)
  • TABLE 68 U.S. EXOSOME THERAPEUTIC MARKET, BY TRANSPORTING CAPACITY, 2017-2026 (USD MILLION)
  • TABLE 69 U.S. BIO MACROMOLECULES IN EXOSOME THERAPEUTIC MARKET, BY TRANSPORTING CAPACITY, 2017-2026 (USD MILLION)
  • TABLE 70 U.S. EXOSOME THERAPEUTIC MARKET, BY APPLICATION, 2017-2026 (USD MILLION)
  • TABLE 71 U.S. ONCOLOGY IN EXOSOME THERAPEUTIC MARKET, BY APPLICATION, 2017-2026 (USD MILLION)
  • TABLE 72 U.S. NEUROLOGY IN EXOSOME THERAPEUTIC MARKET, BY APPLICATION, 2017-2026 (USD MILLION)
  • TABLE 73 U.S. EXOSOME THERAPEUTIC MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)
  • TABLE 74 U.S. EXOSOME THERAPEUTIC MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 75 MEXICO EXOSOME THERAPEUTIC MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 76 MEXICO NATURAL EXOSOMES IN EXOSOME THERAPEUTIC MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 77 MEXICO EXOSOME THERAPEUTIC MARKET, BY SOURCE, 2017-2026 (USD MILLION)
  • TABLE 78 MEXICO BLOOD IN EXOSOME THERAPEUTIC MARKET, BY SOURCE, 2017-2026 (USD MILLION)
  • TABLE 79 MEXICO BODY FLUIDS IN EXOSOME THERAPEUTIC MARKET, BY SOURCE, 2017-2026 (USD MILLION)
  • TABLE 80 MEXICO EXOSOME THERAPEUTIC MARKET, BY THERAPY, 2017-2026 (USD MILLION)
  • TABLE 81 MEXICO EXOSOME THERAPEUTIC MARKET, BY TRANSPORTING CAPACITY, 2017-2026 (USD MILLION)
  • TABLE 82 MEXICO BIO MACROMOLECULES IN EXOSOME THERAPEUTIC MARKET, BY TRANSPORTING CAPACITY, 2017-2026 (USD MILLION)
  • TABLE 83 MEXICO EXOSOME THERAPEUTIC MARKET, BY APPLICATION, 2017-2026 (USD MILLION)
  • TABLE 84 MEXICO ONCOLOGY IN EXOSOME THERAPEUTIC MARKET, BY APPLICATION, 2017-2026 (USD MILLION)
  • TABLE 85 MEXICO NEUROLOGY IN EXOSOME THERAPEUTIC MARKET, BY APPLICATION, 2017-2026 (USD MILLION)
  • TABLE 86 MEXICO EXOSOME THERAPEUTIC MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)
  • TABLE 87 MEXICO EXOSOME THERAPEUTIC MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 88 ASIA-PACIFIC EXOSOME THERAPEUTIC MARKET, BY COUNTRY, 2017-2026 (USD MILLION)
  • TABLE 89 ASIA-PACIFIC EXOSOME THERAPEUTIC MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 90 ASIA-PACIFIC NATURAL EXOSOMES IN EXOSOME THERAPEUTIC MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 91 ASIA-PACIFIC EXOSOME THERAPEUTIC MARKET, BY SOURCE, 2017-2026 (USD MILLION)
  • TABLE 92 ASIA-PACIFIC BLOOD IN EXOSOME THERAPEUTIC MARKET, BY SOURCE, 2017-2026 (USD MILLION)
  • TABLE 93 ASIA-PACIFIC BODY FLUIDS IN EXOSOME THERAPEUTIC MARKET, BY SOURCE, 2017-2026 (USD MILLION)
  • TABLE 94 ASIA-PACIFIC EXOSOME THERAPEUTIC MARKET, BY THERAPY, 2017-2026 (USD MILLION)
  • TABLE 95 ASIA-PACIFIC EXOSOME THERAPEUTIC MARKET, BY TRANSPORTING CAPACITY, 2017-2026 (USD MILLION)
  • TABLE 96 ASIA-PACIFIC BIO MACROMOLECULES IN EXOSOME THERAPEUTIC MARKET, BY TRANSPORTING CAPACITY, 2017-2026 (USD MILLION)
  • TABLE 97 ASIA-PACIFIC EXOSOME THERAPEUTIC MARKET, BY APPLICATION, 2017-2026 (USD MILLION)
  • TABLE 98 ASIA-PACIFIC ONCOLOGY IN EXOSOME THERAPEUTIC MARKET, BY APPLICATION, 2017-2026 (USD MILLION)
  • TABLE 99 ASIA-PACIFIC NEUROLOGY IN EXOSOME THERAPEUTIC MARKET, BY APPLICATION, 2017-2026 (USD MILLION)
  • TABLE 100 ASIA-PACIFIC EXOSOME THERAPEUTIC MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)
  • TABLE 101 ASIA-PACIFIC EXOSOME THERAPEUTIC MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 102 SOUTH KOREA EXOSOME THERAPEUTIC MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 103 SOUTH KOREA NATURAL EXOSOMES IN EXOSOME THERAPEUTIC MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 104 SOUTH KOREA EXOSOME THERAPEUTIC MARKET, BY SOURCE, 2017-2026 (USD MILLION)
  • TABLE 105 SOUTH KOREA BLOOD IN EXOSOME THERAPEUTIC MARKET, BY SOURCE, 2017-2026 (USD MILLION)
  • TABLE 106 SOUTH KOREA BODY FLUIDS IN EXOSOME THERAPEUTIC MARKET, BY SOURCE, 2017-2026 (USD MILLION)
  • TABLE 107 SOUTH KOREA EXOSOME THERAPEUTIC MARKET, BY THERAPY, 2017-2026 (USD MILLION)
  • TABLE 108 SOUTH KOREA EXOSOME THERAPEUTIC MARKET, BY TRANSPORTING CAPACITY, 2017-2026 (USD MILLION)
  • TABLE 109 SOUTH KOREA BIO MACROMOLECULES IN EXOSOME THERAPEUTIC MARKET, BY TRANSPORTING CAPACITY, 2017-2026 (USD MILLION)
  • TABLE 110 SOUTH KOREA EXOSOME THERAPEUTIC MARKET, BY APPLICATION, 2017-2026 (USD MILLION)
  • TABLE 111 SOUTH KOREA ONCOLOGY IN EXOSOME THERAPEUTIC MARKET, BY APPLICATION, 2017-2026 (USD MILLION)
  • TABLE 112 SOUTH KOREA NEUROLOGY IN EXOSOME THERAPEUTIC MARKET, BY APPLICATION, 2017-2026 (USD MILLION)
  • TABLE 113 SOUTH KOREA EXOSOME THERAPEUTIC MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)
  • TABLE 114 SOUTH KOREA EXOSOME THERAPEUTIC MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 115 HONG KONG EXOSOME THERAPEUTIC MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 116 HONG KONG NATURAL EXOSOMES IN EXOSOME THERAPEUTIC MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 117 HONG KONG EXOSOME THERAPEUTIC MARKET, BY SOURCE, 2017-2026 (USD MILLION)
  • TABLE 118 HONG KONG BLOOD IN EXOSOME THERAPEUTIC MARKET, BY SOURCE, 2017-2026 (USD MILLION)
  • TABLE 119 HONG KONG BODY FLUIDS IN EXOSOME THERAPEUTIC MARKET, BY SOURCE, 2017-2026 (USD MILLION)
  • TABLE 120 HONG KONG EXOSOME THERAPEUTIC MARKET, BY THERAPY, 2017-2026 (USD MILLION)
  • TABLE 121 HONG KONG EXOSOME THERAPEUTIC MARKET, BY TRANSPORTING CAPACITY, 2017-2026 (USD MILLION)
  • TABLE 122 HONG KONG BIO MACROMOLECULES IN EXOSOME THERAPEUTIC MARKET, BY TRANSPORTING CAPACITY, 2017-2026 (USD MILLION)
  • TABLE 123 HONG KONG EXOSOME THERAPEUTIC MARKET, BY APPLICATION, 2017-2026 (USD MILLION)
  • TABLE 124 HONG KONG ONCOLOGY IN EXOSOME THERAPEUTIC MARKET, BY APPLICATION, 2017-2026 (USD MILLION)
  • TABLE 125 HONG KONG NEUROLOGY IN EXOSOME THERAPEUTIC MARKET, BY APPLICATION, 2017-2026 (USD MILLION)
  • TABLE 126 HONG KONG EXOSOME THERAPEUTIC MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)
  • TABLE 127 HONG KONG EXOSOME THERAPEUTIC MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 128 AUSTRALIA EXOSOME THERAPEUTIC MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 129 AUSTRALIA NATURAL EXOSOMES IN EXOSOME THERAPEUTIC MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 130 AUSTRALIA EXOSOME THERAPEUTIC MARKET, BY SOURCE, 2017-2026 (USD MILLION)
  • TABLE 131 AUSTRALIA BLOOD IN EXOSOME THERAPEUTIC MARKET, BY SOURCE, 2017-2026 (USD MILLION)
  • TABLE 132 AUSTRALIA BODY FLUIDS IN EXOSOME THERAPEUTIC MARKET, BY SOURCE, 2017-2026 (USD MILLION)
  • TABLE 133 AUSTRALIA EXOSOME THERAPEUTIC MARKET, BY THERAPY, 2017-2026 (USD MILLION)
  • TABLE 134 AUSTRALIA EXOSOME THERAPEUTIC MARKET, BY TRANSPORTING CAPACITY, 2017-2026 (USD MILLION)
  • TABLE 135 AUSTRALIA BIO MACROMOLECULES IN EXOSOME THERAPEUTIC MARKET, BY TRANSPORTING CAPACITY, 2017-2026 (USD MILLION)
  • TABLE 136 AUSTRALIA EXOSOME THERAPEUTIC MARKET, BY APPLICATION, 2017-2026 (USD MILLION)
  • TABLE 137 AUSTRALIA ONCOLOGY IN EXOSOME THERAPEUTIC MARKET, BY APPLICATION, 2017-2026 (USD MILLION)
  • TABLE 138 AUSTRALIA NEUROLOGY IN EXOSOME THERAPEUTIC MARKET, BY APPLICATION, 2017-2026 (USD MILLION)
  • TABLE 139 AUSTRALIA EXOSOME THERAPEUTIC MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)
  • TABLE 140 AUSTRALIA EXOSOME THERAPEUTIC MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 141 LATIN AMERICA EXOSOME THERAPEUTIC MARKET, BY COUNTRY, 2017-2026 (USD MILLION)
  • TABLE 142 LATIN AMERICA EXOSOME THERAPEUTIC MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 143 LATIN AMERICA NATURAL EXOSOMES IN EXOSOME THERAPEUTIC MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 144 LATIN AMERICA EXOSOME THERAPEUTIC MARKET, BY SOURCE, 2017-2026 (USD MILLION)
  • TABLE 145 LATIN AMERICA BLOOD IN EXOSOME THERAPEUTIC MARKET, BY SOURCE, 2017-2026 (USD MILLION)
  • TABLE 146 LATIN AMERICA BODY FLUIDS IN EXOSOME THERAPEUTIC MARKET, BY SOURCE, 2017-2026 (USD MILLION)
  • TABLE 147 LATIN AMERICA EXOSOME THERAPEUTIC MARKET, BY THERAPY, 2017-2026 (USD MILLION)
  • TABLE 148 LATIN AMERICA EXOSOME THERAPEUTIC MARKET, BY TRANSPORTING CAPACITY, 2017-2026 (USD MILLION)
  • TABLE 149 LATIN AMERICA BIO MACROMOLECULES IN EXOSOME THERAPEUTIC MARKET, BY TRANSPORTING CAPACITY, 2017-2026 (USD MILLION)
  • TABLE 150 LATIN AMERICA EXOSOME THERAPEUTIC MARKET, BY APPLICATION, 2017-2026 (USD MILLION)
  • TABLE 151 LATIN AMERICA ONCOLOGY IN EXOSOME THERAPEUTIC MARKET, BY APPLICATION, 2017-2026 (USD MILLION)
  • TABLE 152 LATIN AMERICA NEUROLOGY IN EXOSOME THERAPEUTIC MARKET, BY APPLICATION, 2017-2026 (USD MILLION)
  • TABLE 153 LATIN AMERICA EXOSOME THERAPEUTIC MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)
  • TABLE 154 LATIN AMERICA EXOSOME THERAPEUTIC MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 155 ARGENTINA EXOSOME THERAPEUTIC MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 156 ARGENTINA NATURAL EXOSOMES IN EXOSOME THERAPEUTIC MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 157 ARGENTINA EXOSOME THERAPEUTIC MARKET, BY SOURCE, 2017-2026 (USD MILLION)
  • TABLE 158 ARGENTINA BLOOD IN EXOSOME THERAPEUTIC MARKET, BY SOURCE, 2017-2026 (USD MILLION)
  • TABLE 159 ARGENTINA BODY FLUIDS IN EXOSOME THERAPEUTIC MARKET, BY SOURCE, 2017-2026 (USD MILLION)
  • TABLE 160 ARGENTINA EXOSOME THERAPEUTIC MARKET, BY THERAPY, 2017-2026 (USD MILLION)
  • TABLE 161 ARGENTINA EXOSOME THERAPEUTIC MARKET, BY TRANSPORTING CAPACITY, 2017-2026 (USD MILLION)
  • TABLE 162 ARGENTINA BIO MACROMOLECULES IN EXOSOME THERAPEUTIC MARKET, BY TRANSPORTING CAPACITY, 2017-2026 (USD MILLION)
  • TABLE 163 ARGENTINA EXOSOME THERAPEUTIC MARKET, BY APPLICATION, 2017-2026 (USD MILLION)
  • TABLE 164 ARGENTINA ONCOLOGY IN EXOSOME THERAPEUTIC MARKET, BY APPLICATION, 2017-2026 (USD MILLION)
  • TABLE 165 ARGENTINA NEUROLOGY IN EXOSOME THERAPEUTIC MARKET, BY APPLICATION, 2017-2026 (USD MILLION)
  • TABLE 166 ARGENTINA EXOSOME THERAPEUTIC MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)
  • TABLE 167 ARGENTINA EXOSOME THERAPEUTIC MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 168 COLOMBIA EXOSOME THERAPEUTIC MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 169 COLOMBIA NATURAL EXOSOMES IN EXOSOME THERAPEUTIC MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 170 COLOMBIA EXOSOME THERAPEUTIC MARKET, BY SOURCE, 2017-2026 (USD MILLION)
  • TABLE 171 COLOMBIA BLOOD IN EXOSOME THERAPEUTIC MARKET, BY SOURCE, 2017-2026 (USD MILLION)
  • TABLE 172 COLOMBIA BODY FLUIDS IN EXOSOME THERAPEUTIC MARKET, BY SOURCE, 2017-2026 (USD MILLION)
  • TABLE 173 COLOMBIA EXOSOME THERAPEUTIC MARKET, BY THERAPY, 2017-2026 (USD MILLION)
  • TABLE 174 COLOMBIA EXOSOME THERAPEUTIC MARKET, BY TRANSPORTING CAPACITY, 2017-2026 (USD MILLION)
  • TABLE 175 COLOMBIA BIO MACROMOLECULES IN EXOSOME THERAPEUTIC MARKET, BY TRANSPORTING CAPACITY, 2017-2026 (USD MILLION)
  • TABLE 176 COLOMBIA EXOSOME THERAPEUTIC MARKET, BY APPLICATION, 2017-2026 (USD MILLION)
  • TABLE 177 COLOMBIA ONCOLOGY IN EXOSOME THERAPEUTIC MARKET, BY APPLICATION, 2017-2026 (USD MILLION)
  • TABLE 178 COLOMBIA NEUROLOGY IN EXOSOME THERAPEUTIC MARKET, BY APPLICATION, 2017-2026 (USD MILLION)
  • TABLE 179 COLOMBIA EXOSOME THERAPEUTIC MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)
  • TABLE 180 COLOMBIA EXOSOME THERAPEUTIC MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 181 PERU EXOSOME THERAPEUTIC MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 182 PERU NATURAL EXOSOMES IN EXOSOME THERAPEUTIC MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 183 PERU EXOSOME THERAPEUTIC MARKET, BY SOURCE, 2017-2026 (USD MILLION)
  • TABLE 184 PERU BLOOD IN EXOSOME THERAPEUTIC MARKET, BY SOURCE, 2017-2026 (USD MILLION)
  • TABLE 185 PERU BODY FLUIDS IN EXOSOME THERAPEUTIC MARKET, BY SOURCE, 2017-2026 (USD MILLION)
  • TABLE 186 PERU EXOSOME THERAPEUTIC MARKET, BY THERAPY, 2017-2026 (USD MILLION)
  • TABLE 187 PERU EXOSOME THERAPEUTIC MARKET, BY TRANSPORTING CAPACITY, 2017-2026 (USD MILLION)
  • TABLE 188 PERU BIO MACROMOLECULES IN EXOSOME THERAPEUTIC MARKET, BY TRANSPORTING CAPACITY, 2017-2026 (USD MILLION)
  • TABLE 189 PERU EXOSOME THERAPEUTIC MARKET, BY APPLICATION, 2017-2026 (USD MILLION)
  • TABLE 190 PERU ONCOLOGY IN EXOSOME THERAPEUTIC MARKET, BY APPLICATION, 2017-2026 (USD MILLION)
  • TABLE 191 PERU NEUROLOGY IN EXOSOME THERAPEUTIC MARKET, BY APPLICATION, 2017-2026 (USD MILLION)
  • TABLE 192 PERU EXOSOME THERAPEUTIC MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)
  • TABLE 193 PERU EXOSOME THERAPEUTIC MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 194 CHILE EXOSOME THERAPEUTIC MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 195 CHILE NATURAL EXOSOMES IN EXOSOME THERAPEUTIC MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 196 CHILE EXOSOME THERAPEUTIC MARKET, BY SOURCE, 2017-2026 (USD MILLION)
  • TABLE 197 CHILE BLOOD IN EXOSOME THERAPEUTIC MARKET, BY SOURCE, 2017-2026 (USD MILLION)
  • TABLE 198 CHILE BODY FLUIDS IN EXOSOME THERAPEUTIC MARKET, BY SOURCE, 2017-2026 (USD MILLION)
  • TABLE 199 CHILE EXOSOME THERAPEUTIC MARKET, BY THERAPY, 2017-2026 (USD MILLION)
  • TABLE 200 CHILE EXOSOME THERAPEUTIC MARKET, BY TRANSPORTING CAPACITY, 2017-2026 (USD MILLION)
  • TABLE 201 CHILE BIO MACROMOLECULES IN EXOSOME THERAPEUTIC MARKET, BY TRANSPORTING CAPACITY, 2017-2026 (USD MILLION)
  • TABLE 202 CHILE EXOSOME THERAPEUTIC MARKET, BY APPLICATION, 2017-2026 (USD MILLION)
  • TABLE 203 CHILE ONCOLOGY IN EXOSOME THERAPEUTIC MARKET, BY APPLICATION, 2017-2026 (USD MILLION)
  • TABLE 204 CHILE NEUROLOGY IN EXOSOME THERAPEUTIC MARKET, BY APPLICATION, 2017-2026 (USD MILLION)
  • TABLE 205 CHILE EXOSOME THERAPEUTIC MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)
  • TABLE 206 CHILE EXOSOME THERAPEUTIC MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 207 ECUADOR EXOSOME THERAPEUTIC MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 208 ECUADOR NATURAL EXOSOMES IN EXOSOME THERAPEUTIC MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 209 ECUADOR EXOSOME THERAPEUTIC MARKET, BY SOURCE, 2017-2026 (USD MILLION)
  • TABLE 210 ECUADOR BLOOD IN EXOSOME THERAPEUTIC MARKET, BY SOURCE, 2017-2026 (USD MILLION)
  • TABLE 211 ECUADOR BODY FLUIDS IN EXOSOME THERAPEUTIC MARKET, BY SOURCE, 2017-2026 (USD MILLION)
  • TABLE 212 ECUADOR EXOSOME THERAPEUTIC MARKET, BY THERAPY, 2017-2026 (USD MILLION)
  • TABLE 213 ECUADOR EXOSOME THERAPEUTIC MARKET, BY TRANSPORTING CAPACITY, 2017-2026 (USD MILLION)
  • TABLE 214 ECUADOR BIO MACROMOLECULES IN EXOSOME THERAPEUTIC MARKET, BY TRANSPORTING CAPACITY, 2017-2026 (USD MILLION)
  • TABLE 215 ECUADOR EXOSOME THERAPEUTIC MARKET, BY APPLICATION, 2017-2026 (USD MILLION)
  • TABLE 216 ECUADOR ONCOLOGY IN EXOSOME THERAPEUTIC MARKET, BY APPLICATION, 2017-2026 (USD MILLION)
  • TABLE 217 ECUADOR NEUROLOGY IN EXOSOME THERAPEUTIC MARKET, BY APPLICATION, 2017-2026 (USD MILLION)
  • TABLE 218 ECUADOR EXOSOME THERAPEUTIC MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)
  • TABLE 219 ECUADOR EXOSOME THERAPEUTIC MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 220 VENEZUELA EXOSOME THERAPEUTIC MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 221 VENEZUELA NATURAL EXOSOMES IN EXOSOME THERAPEUTIC MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 222 VENEZUELA EXOSOME THERAPEUTIC MARKET, BY SOURCE, 2017-2026 (USD MILLION)
  • TABLE 223 VENEZUELA BLOOD IN EXOSOME THERAPEUTIC MARKET, BY SOURCE, 2017-2026 (USD MILLION)
  • TABLE 224 VENEZUELA BODY FLUIDS IN EXOSOME THERAPEUTIC MARKET, BY SOURCE, 2017-2026 (USD MILLION)
  • TABLE 225 VENEZUELA EXOSOME THERAPEUTIC MARKET, BY THERAPY, 2017-2026 (USD MILLION)
  • TABLE 226 VENEZUELA EXOSOME THERAPEUTIC MARKET, BY TRANSPORTING CAPACITY, 2017-2026 (USD MILLION)
  • TABLE 227 VENEZUELA BIO MACROMOLECULES IN EXOSOME THERAPEUTIC MARKET, BY TRANSPORTING CAPACITY, 2017-2026 (USD MILLION)
  • TABLE 228 VENEZUELA EXOSOME THERAPEUTIC MARKET, BY APPLICATION, 2017-2026 (USD MILLION)
  • TABLE 229 VENEZUELA ONCOLOGY IN EXOSOME THERAPEUTIC MARKET, BY APPLICATION, 2017-2026 (USD MILLION)
  • TABLE 230 VENEZUELA NEUROLOGY IN EXOSOME THERAPEUTIC MARKET, BY APPLICATION, 2017-2026 (USD MILLION)
  • TABLE 231 VENEZUELA EXOSOME THERAPEUTIC MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)
  • TABLE 232 VENEZUELA EXOSOME THERAPEUTIC MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 233 PANAMA EXOSOME THERAPEUTIC MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 234 PANAMA NATURAL EXOSOMES IN EXOSOME THERAPEUTIC MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 235 PANAMA EXOSOME THERAPEUTIC MARKET, BY SOURCE, 2017-2026 (USD MILLION)
  • TABLE 236 PANAMA BLOOD IN EXOSOME THERAPEUTIC MARKET, BY SOURCE, 2017-2026 (USD MILLION)
  • TABLE 237 PANAMA BODY FLUIDS IN EXOSOME THERAPEUTIC MARKET, BY SOURCE, 2017-2026 (USD MILLION)
  • TABLE 238 PANAMA EXOSOME THERAPEUTIC MARKET, BY THERAPY, 2017-2026 (USD MILLION)
  • TABLE 239 PANAMA EXOSOME THERAPEUTIC MARKET, BY TRANSPORTING CAPACITY, 2017-2026 (USD MILLION)
  • TABLE 240 PANAMA BIO MACROMOLECULES IN EXOSOME THERAPEUTIC MARKET, BY TRANSPORTING CAPACITY, 2017-2026 (USD MILLION)
  • TABLE 241 PANAMA EXOSOME THERAPEUTIC MARKET, BY APPLICATION, 2017-2026 (USD MILLION)
  • TABLE 242 PANAMA ONCOLOGY IN EXOSOME THERAPEUTIC MARKET, BY APPLICATION, 2017-2026 (USD MILLION)
  • TABLE 243 PANAMA NEUROLOGY IN EXOSOME THERAPEUTIC MARKET, BY APPLICATION, 2017-2026 (USD MILLION)
  • TABLE 244 PANAMA EXOSOME THERAPEUTIC MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)
  • TABLE 245 PANAMA EXOSOME THERAPEUTIC MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 246 DOMINICAN REPUBLIC EXOSOME THERAPEUTIC MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 247 DOMINICAN REPUBLIC NATURAL EXOSOMES IN EXOSOME THERAPEUTIC MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 248 DOMINICAN REPUBLIC EXOSOME THERAPEUTIC MARKET, BY SOURCE, 2017-2026 (USD MILLION)
  • TABLE 249 DOMINICAN REPUBLIC BLOOD IN EXOSOME THERAPEUTIC MARKET, BY SOURCE, 2017-2026 (USD MILLION)
  • TABLE 250 DOMINICAN REPUBLIC BODY FLUIDS IN EXOSOME THERAPEUTIC MARKET, BY SOURCE, 2017-2026 (USD MILLION)
  • TABLE 251 DOMINICAN REPUBLIC EXOSOME THERAPEUTIC MARKET, BY THERAPY, 2017-2026 (USD MILLION)
  • TABLE 252 DOMINICAN REPUBLIC EXOSOME THERAPEUTIC MARKET, BY TRANSPORTING CAPACITY, 2017-2026 (USD MILLION)
  • TABLE 253 DOMINICAN REPUBLIC BIO MACROMOLECULES IN EXOSOME THERAPEUTIC MARKET, BY TRANSPORTING CAPACITY, 2017-2026 (USD MILLION)
  • TABLE 254 DOMINICAN REPUBLIC EXOSOME THERAPEUTIC MARKET, BY APPLICATION, 2017-2026 (USD MILLION)
  • TABLE 255 DOMINICAN REPUBLIC ONCOLOGY IN EXOSOME THERAPEUTIC MARKET, BY APPLICATION, 2017-2026 (USD MILLION)
  • TABLE 256 DOMINICAN REPUBLIC NEUROLOGY IN EXOSOME THERAPEUTIC MARKET, BY APPLICATION, 2017-2026 (USD MILLION)
  • TABLE 257 DOMINICAN REPUBLIC EXOSOME THERAPEUTIC MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)
  • TABLE 258 DOMINICAN REPUBLIC EXOSOME THERAPEUTIC MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 259 EL SALVADOR EXOSOME THERAPEUTIC MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 260 EL SALVADOR NATURAL EXOSOMES IN EXOSOME THERAPEUTIC MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 261 EL SALVADOR EXOSOME THERAPEUTIC MARKET, BY SOURCE, 2017-2026 (USD MILLION)
  • TABLE 262 EL SALVADOR BLOOD IN EXOSOME THERAPEUTIC MARKET, BY SOURCE, 2017-2026 (USD MILLION)
  • TABLE 263 EL SALVADOR BODY FLUIDS IN EXOSOME THERAPEUTIC MARKET, BY SOURCE, 2017-2026 (USD MILLION)
  • TABLE 264 EL SALVADOR EXOSOME THERAPEUTIC MARKET, BY THERAPY, 2017-2026 (USD MILLION)
  • TABLE 265 EL SALVADOR EXOSOME THERAPEUTIC MARKET, BY TRANSPORTING CAPACITY, 2017-2026 (USD MILLION)
  • TABLE 266 EL SALVADOR BIO MACROMOLECULES IN EXOSOME THERAPEUTIC MARKET, BY TRANSPORTING CAPACITY, 2017-2026 (USD MILLION)
  • TABLE 267 EL SALVADOR EXOSOME THERAPEUTIC MARKET, BY APPLICATION, 2017-2026 (USD MILLION)
  • TABLE 268 EL SALVADOR ONCOLOGY IN EXOSOME THERAPEUTIC MARKET, BY APPLICATION, 2017-2026 (USD MILLION)
  • TABLE 269 EL SALVADOR NEUROLOGY IN EXOSOME THERAPEUTIC MARKET, BY APPLICATION, 2017-2026 (USD MILLION)
  • TABLE 270 EL SALVADOR EXOSOME THERAPEUTIC MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)
  • TABLE 271 EL SALVADOR EXOSOME THERAPEUTIC MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 272 PARAGUAY EXOSOME THERAPEUTIC MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 273 PARAGUAY NATURAL EXOSOMES IN EXOSOME THERAPEUTIC MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 274 PARAGUAY EXOSOME THERAPEUTIC MARKET, BY SOURCE, 2017-2026 (USD MILLION)
  • TABLE 275 PARAGUAY BLOOD IN EXOSOME THERAPEUTIC MARKET, BY SOURCE, 2017-2026 (USD MILLION)
  • TABLE 276 PARAGUAY BODY FLUIDS IN EXOSOME THERAPEUTIC MARKET, BY SOURCE, 2017-2026 (USD MILLION)
  • TABLE 277 PARAGUAY EXOSOME THERAPEUTIC MARKET, BY THERAPY, 2017-2026 (USD MILLION)
  • TABLE 278 PARAGUAY EXOSOME THERAPEUTIC MARKET, BY TRANSPORTING CAPACITY, 2017-2026 (USD MILLION)
  • TABLE 279 PARAGUAY BIO MACROMOLECULES IN EXOSOME THERAPEUTIC MARKET, BY TRANSPORTING CAPACITY, 2017-2026 (USD MILLION)
  • TABLE 280 PARAGUAY EXOSOME THERAPEUTIC MARKET, BY APPLICATION, 2017-2026 (USD MILLION)
  • TABLE 281 PARAGUAY ONCOLOGY IN EXOSOME THERAPEUTIC MARKET, BY APPLICATION, 2017-2026 (USD MILLION)
  • TABLE 282 PARAGUAY NEUROLOGY IN EXOSOME THERAPEUTIC MARKET, BY APPLICATION, 2017-2026 (USD MILLION)
  • TABLE 283 PARAGUAY EXOSOME THERAPEUTIC MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)
  • TABLE 284 PARAGUAY EXOSOME THERAPEUTIC MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 285 COSTA RICA EXOSOME THERAPEUTIC MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 286 COSTA RICA NATURAL EXOSOMES IN EXOSOME THERAPEUTIC MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 287 COSTA RICA EXOSOME THERAPEUTIC MARKET, BY SOURCE, 2017-2026 (USD MILLION)
  • TABLE 288 COSTA RICA BLOOD IN EXOSOME THERAPEUTIC MARKET, BY SOURCE, 2017-2026 (USD MILLION)
  • TABLE 289 COSTA RICA BODY FLUIDS IN EXOSOME THERAPEUTIC MARKET, BY SOURCE, 2017-2026 (USD MILLION)
  • TABLE 290 COSTA RICA EXOSOME THERAPEUTIC MARKET, BY THERAPY, 2017-2026 (USD MILLION)
  • TABLE 291 COSTA RICA EXOSOME THERAPEUTIC MARKET, BY TRANSPORTING CAPACITY, 2017-2026 (USD MILLION)
  • TABLE 292 COSTA RICA BIO MACROMOLECULES IN EXOSOME THERAPEUTIC MARKET, BY TRANSPORTING CAPACITY, 2017-2026 (USD MILLION)
  • TABLE 293 COSTA RICA EXOSOME THERAPEUTIC MARKET, BY APPLICATION, 2017-2026 (USD MILLION)
  • TABLE 294 COSTA RICA ONCOLOGY IN EXOSOME THERAPEUTIC MARKET, BY APPLICATION, 2017-2026 (USD MILLION)
  • TABLE 295 COSTA RICA NEUROLOGY IN EXOSOME THERAPEUTIC MARKET, BY APPLICATION, 2017-2026 (USD MILLION)
  • TABLE 296 COSTA RICA EXOSOME THERAPEUTIC MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)
  • TABLE 297 COSTA RICA EXOSOME THERAPEUTIC MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 298 PUERTO RICO EXOSOME THERAPEUTIC MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 299 PUERTO RICO NATURAL EXOSOMES IN EXOSOME THERAPEUTIC MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 300 PUERTO RICO EXOSOME THERAPEUTIC MARKET, BY SOURCE, 2017-2026 (USD MILLION)
  • TABLE 301 PUERTO RICO BLOOD IN EXOSOME THERAPEUTIC MARKET, BY SOURCE, 2017-2026 (USD MILLION)
  • TABLE 302 PUERTO RICO BODY FLUIDS IN EXOSOME THERAPEUTIC MARKET, BY SOURCE, 2017-2026 (USD MILLION)
  • TABLE 303 PUERTO RICO EXOSOME THERAPEUTIC MARKET, BY THERAPY, 2017-2026 (USD MILLION)
  • TABLE 304 PUERTO RICO EXOSOME THERAPEUTIC MARKET, BY TRANSPORTING CAPACITY, 2017-2026 (USD MILLION)
  • TABLE 305 PUERTO RICO BIO MACROMOLECULES IN EXOSOME THERAPEUTIC MARKET, BY TRANSPORTING CAPACITY, 2017-2026 (USD MILLION)
  • TABLE 306 PUERTO RICO EXOSOME THERAPEUTIC MARKET, BY APPLICATION, 2017-2026 (USD MILLION)
  • TABLE 307 PUERTO RICO ONCOLOGY IN EXOSOME THERAPEUTIC MARKET, BY APPLICATION, 2017-2026 (USD MILLION)
  • TABLE 308 PUERTO RICO NEUROLOGY IN EXOSOME THERAPEUTIC MARKET, BY APPLICATION, 2017-2026 (USD MILLION)
  • TABLE 309 PUERTO RICO EXOSOME THERAPEUTIC MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)
  • TABLE 310 PUERTO RICO EXOSOME THERAPEUTIC MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 311 NICARAGUA EXOSOME THERAPEUTIC MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 312 NICARAGUA NATURAL EXOSOMES IN EXOSOME THERAPEUTIC MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 313 NICARAGUA EXOSOME THERAPEUTIC MARKET, BY SOURCE, 2017-2026 (USD MILLION)
  • TABLE 314 NICARAGUA BLOOD IN EXOSOME THERAPEUTIC MARKET, BY SOURCE, 2017-2026 (USD MILLION)
  • TABLE 315 NICARAGUA BODY FLUIDS IN EXOSOME THERAPEUTIC MARKET, BY SOURCE, 2017-2026 (USD MILLION)
  • TABLE 316 NICARAGUA EXOSOME THERAPEUTIC MARKET, BY THERAPY, 2017-2026 (USD MILLION)
  • TABLE 317 NICARAGUA EXOSOME THERAPEUTIC MARKET, BY TRANSPORTING CAPACITY, 2017-2026 (USD MILLION)
  • TABLE 318 NICARAGUA BIO MACROMOLECULES IN EXOSOME THERAPEUTIC MARKET, BY TRANSPORTING CAPACITY, 2017-2026 (USD MILLION)
  • TABLE 319 NICARAGUA EXOSOME THERAPEUTIC MARKET, BY APPLICATION, 2017-2026 (USD MILLION)
  • TABLE 320 NICARAGUA ONCOLOGY IN EXOSOME THERAPEUTIC MARKET, BY APPLICATION, 2017-2026 (USD MILLION)
  • TABLE 321 NICARAGUA NEUROLOGY IN EXOSOME THERAPEUTIC MARKET, BY APPLICATION, 2017-2026 (USD MILLION)
  • TABLE 322 NICARAGUA EXOSOME THERAPEUTIC MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)
  • TABLE 323 NICARAGUA EXOSOME THERAPEUTIC MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 324 URUGUAY EXOSOME THERAPEUTIC MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 325 URUGUAY NATURAL EXOSOMES IN EXOSOME THERAPEUTIC MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 326 URUGUAY EXOSOME THERAPEUTIC MARKET, BY SOURCE, 2017-2026 (USD MILLION)
  • TABLE 327 URUGUAY BLOOD IN EXOSOME THERAPEUTIC MARKET, BY SOURCE, 2017-2026 (USD MILLION)
  • TABLE 328 URUGUAY BODY FLUIDS IN EXOSOME THERAPEUTIC MARKET, BY SOURCE, 2017-2026 (USD MILLION)
  • TABLE 329 URUGUAY EXOSOME THERAPEUTIC MARKET, BY THERAPY, 2017-2026 (USD MILLION)
  • TABLE 330 URUGUAY EXOSOME THERAPEUTIC MARKET, BY TRANSPORTING CAPACITY, 2017-2026 (USD MILLION)
  • TABLE 331 URUGUAY BIO MACROMOLECULES IN EXOSOME THERAPEUTIC MARKET, BY TRANSPORTING CAPACITY, 2017-2026 (USD MILLION)
  • TABLE 332 URUGUAY EXOSOME THERAPEUTIC MARKET, BY APPLICATION, 2017-2026 (USD MILLION)
  • TABLE 333 URUGUAY ONCOLOGY IN EXOSOME THERAPEUTIC MARKET, BY APPLICATION, 2017-2026 (USD MILLION)
  • TABLE 334 URUGUAY NEUROLOGY IN EXOSOME THERAPEUTIC MARKET, BY APPLICATION, 2017-2026 (USD MILLION)
  • TABLE 335 URUGUAY EXOSOME THERAPEUTIC MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)
  • TABLE 336 URUGUAY EXOSOME THERAPEUTIC MARKET, BY END USER, 2017-2026 (USD MILLION)
  • TABLE 337 TURKEY EXOSOME THERAPEUTIC MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 338 TURKEY NATURAL EXOSOMES IN EXOSOME THERAPEUTIC MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • TABLE 339 TURKEY EXOSOME THERAPEUTIC MARKET, BY SOURCE, 2017-2026 (USD MILLION)
  • TABLE 340 TURKEY BLOOD IN EXOSOME THERAPEUTIC MARKET, BY SOURCE, 2017-2026 (USD MILLION)
  • TABLE 341 TURKEY BODY FLUIDS IN EXOSOME THERAPEUTIC MARKET, BY SOURCE, 2017-2026 (USD MILLION)
  • TABLE 342 TURKEY EXOSOME THERAPEUTIC MARKET, BY THERAPY, 2017-2026 (USD MILLION)
  • TABLE 343 TURKEY EXOSOME THERAPEUTIC MARKET, BY TRANSPORTING CAPACITY, 2017-2026 (USD MILLION)
  • TABLE 344 TURKEY BIO MACROMOLECULES IN EXOSOME THERAPEUTIC MARKET, BY TRANSPORTING CAPACITY, 2017-2026 (USD MILLION)
  • TABLE 345 TURKEY EXOSOME THERAPEUTIC MARKET, BY APPLICATION, 2017-2026 (USD MILLION)
  • TABLE 346 TURKEY ONCOLOGY IN EXOSOME THERAPEUTIC MARKET, BY APPLICATION, 2017-2026 (USD MILLION)
  • TABLE 347 TURKEY NEUROLOGY IN EXOSOME THERAPEUTIC MARKET, BY APPLICATION, 2017-2026 (USD MILLION)
  • TABLE 348 TURKEY EXOSOME THERAPEUTIC MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)
  • TABLE 349 TURKEY EXOSOME THERAPEUTIC MARKET, BY END USER, 2017-2026 (USD MILLION)

LIST OF FIGURES

  • FIGURE 1 GLOBAL EXOSOME THERAPEUTIC MARKET: SEGMENTATION
  • FIGURE 2 GLOBAL EXOSOME THERAPEUTIC MARKET: DATA TRIANGULATION
  • FIGURE 3 GLOBAL EXOSOME THERAPEUTIC MARKET: DROC ANALYSIS
  • FIGURE 4 GLOBAL EXOSOME THERAPEUTIC MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS
  • FIGURE 5 GLOBAL EXOSOME THERAPEUTIC MARKET: COMPANY RESEARCH ANALYSIS
  • FIGURE 6 GLOBAL EXOSOME THERAPEUTIC MARKET: INTERVIEW DEMOGRAPHICS
  • FIGURE 7 DRIVERS, RESTRAINT, OPPORTUNITIES AND CHALLENGE OF GLOBAL EXOSOME THERAPEUTIC MARKET
  • FIGURE 8 LYME DISEASE-REPORTED CONFIRMED AND PROBABLE CASES BY SEX OF PATIENT, UNITED STATES, 2017
  • FIGURE 9 COLORECTAL CANCER RATES PER 100,000 IN 2018: BOTH SEXES
  • FIGURE 10 COLORECTAL CANCER RATES IN 2018 PER 100,000 FOR MEN AND WOMEN
  • FIGURE 11 COLON & RECTUM CANCER SURVIVORS FROM 2016 TO 2026
  • FIGURE 12 AGEING WORLD POPULATION (NUMBER OF PERSONS AGED 60 YEARS OR OLDER IN MILLIONS)
  • FIGURE 13 AGEING NORTH AMERICA POPULATION (IN MILLION)
  • FIGURE 14 AGEING EUROPE POPULATION (IN MILLION)
  • FIGURE 15 AGEING ASIA-PACIFIC POPULATION (IN MILLION)
  • FIGURE 16 HEALTH SPENDING BY MAJOR SOURCES OF FUNDS
  • FIGURE 17 GLOBAL EXOSOME THERAPEUTIC MARKET: SEGMENTATION
  • FIGURE 18 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL EXOSOME THERAPEUTIC MARKET AND EUROPE IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2019 TO 2026
  • FIGURE 19 INCREASING PREVALENCE OF LYME DISEASE, CHRONIC INFLAMMATION, AUTOIMMUNE DISEASE AND OTHER CHRONIC DEGENERATIVE DISEASES IS DRIVING THE GLOBAL EXOSOME THERAPEUTIC MARKET IN THE FORECAST PERIOD OF 2019 TO 2026
  • FIGURE 20 HYBRID EXOSOMES IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL EXOSOME THERAPEUTIC MARKET IN 2019 & 2026
  • FIGURE 21 EUROPE IS THE FASTEST GROWING MARKET FOR EXOSOME THERAPEUTIC MANUFACTURERS IN THE FORECAST PERIOD OF 2019 TO 2026
  • FIGURE 22 GLOBAL EXOSOME THERAPEUTIC MARKET, BY TYPE (2018)
  • FIGURE 23 GLOBAL EXOSOME THERAPEUTIC MARKET, BY TYPE, 2017-2026 (USD MILLION)
  • FIGURE 24 GLOBAL EXOSOME THERAPEUTIC MARKET, BY TYPE, CAGR (2019-2026)
  • FIGURE 25 GLOBAL EXOSOME THERAPEUTIC MARKET, BY TYPE, LIFELINE CURVE
  • FIGURE 26 GLOBAL EXOSOME THERAPEUTIC MARKET, BY SOURCE (2018)
  • FIGURE 27 GLOBAL EXOSOME THERAPEUTIC MARKET, BY SOURCE, 2017-2026 (USD MILLION)
  • FIGURE 28 GLOBAL EXOSOME THERAPEUTIC MARKET, BY SOURCE, CAGR (2019-2026)
  • FIGURE 29 GLOBAL EXOSOME THERAPEUTIC MARKET, BY SOURCE, LIFELINE CURVE
  • FIGURE 30 GLOBAL EXOSOME THERAPEUTIC MARKET, BY THERAPY (2018)
  • FIGURE 31 GLOBAL EXOSOME THERAPEUTIC MARKET, BY THERAPY, 2017-2026 (USD MILLION)
  • FIGURE 32 GLOBAL EXOSOME THERAPEUTIC MARKET, BY THERAPY, CAGR (2019-2026)
  • FIGURE 33 GLOBAL EXOSOME THERAPEUTIC MARKET, BY THERAPY, LIFELINE CURVE
  • FIGURE 34 GLOBAL EXOSOME THERAPEUTIC MARKET, BY TRANSPORTING CAPACITY (2018)
  • FIGURE 35 GLOBAL EXOSOME THERAPEUTIC MARKET, BY TRANSPORTING CAPACITY, 2017-2026 (USD MILLION)
  • FIGURE 36 GLOBAL EXOSOME THERAPEUTIC MARKET, BY TRANSPORTING CAPACITY, CAGR (2019-2026)
  • FIGURE 37 GLOBAL EXOSOME THERAPEUTIC MARKET, BY TRANSPORTING CAPACITY, LIFELINE CURVE
  • FIGURE 38 GLOBAL EXOSOME THERAPEUTIC MARKET, BY APPLICATION (2018)
  • FIGURE 39 GLOBAL EXOSOME THERAPEUTIC MARKET, BY APPLICATION, 2017-2026 (USD MILLION)
  • FIGURE 40 GLOBAL EXOSOME THERAPEUTIC MARKET, BY APPLICATION, CAGR (2019-2026)
  • FIGURE 41 GLOBAL EXOSOME THERAPEUTIC MARKET, BY APPLICATION, LIFELINE CURVE
  • FIGURE 42 GLOBAL EXOSOME THERAPEUTIC MARKET, BY ROUTE OF ADMINISTRATION (2018)
  • FIGURE 43 GLOBAL EXOSOME THERAPEUTIC MARKET, BY ROUTE OF ADMINISTRATION, 2017-2026 (USD MILLION)
  • FIGURE 44 GLOBAL EXOSOME THERAPEUTIC MARKET, BY ROUTE OF ADMINISTRATION, CAGR (2019-2026)
  • FIGURE 45 GLOBAL EXOSOME THERAPEUTIC MARKET, BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
  • FIGURE 46 GLOBAL EXOSOME THERAPEUTIC MARKET, BY END USER (2018)
  • FIGURE 47 GLOBAL EXOSOME THERAPEUTIC MARKET, BY END USER, 2017-2026 (USD MILLION)
  • FIGURE 48 GLOBAL EXOSOME THERAPEUTIC MARKET, BY END USER, CAGR (2019-2026)
  • FIGURE 49 GLOBAL EXOSOME THERAPEUTIC MARKET, BY END USER, LIFELINE CURVE
  • FIGURE 50 GLOBAL EXOSOME THERAPEUTIC MARKET: SNAPSHOT (2018)
  • FIGURE 51 GLOBAL EXOSOME THERAPEUTIC MARKET: BY GEOGRAPHY (2018)
  • FIGURE 52 GLOBAL EXOSOME THERAPEUTIC MARKET: BY GEOGRAPHY (2019 & 2026)
  • FIGURE 53 GLOBAL EXOSOME THERAPEUTIC MARKET: BY GEOGRAPHY (2018 & 2026)
  • FIGURE 54 GLOBAL EXOSOME THERAPEUTIC MARKET: BY TYPE (2019-2026)
  • FIGURE 55 NORTH AMERICA EXOSOME THERAPEUTIC MARKET: SNAPSHOT (2018)
  • FIGURE 56 NORTH AMERICA EXOSOME THERAPEUTIC MARKET: BY COUNTRY (2018)
  • FIGURE 57 NORTH AMERICA EXOSOME THERAPEUTIC MARKET: BY COUNTRY (2019 & 2026)
  • FIGURE 58 NORTH AMERICA EXOSOME THERAPEUTIC MARKET: BY COUNTRY (2018 & 2026)
  • FIGURE 59 NORTH AMERICA EXOSOME THERAPEUTIC MARKET: BY TYPE (2019-2026)
  • FIGURE 60 ASIA-PACIFIC EXOSOME THERAPEUTIC MARKET: SNAPSHOT (2018)
  • FIGURE 61 ASIA-PACIFIC EXOSOME THERAPEUTIC MARKET: BY COUNTRY (2018)
  • FIGURE 62 ASIA-PACIFIC EXOSOME THERAPEUTIC MARKET: BY COUNTRY (2019 & 2026)
  • FIGURE 63 ASIA-PACIFIC EXOSOME THERAPEUTIC MARKET: BY COUNTRY (2018 & 2026)
  • FIGURE 64 ASIA-PACIFIC EXOSOME THERAPEUTIC MARKET: BY TYPE (2019-2026)
  • FIGURE 65 LATIN AMERICA EXOSOME THERAPEUTIC MARKET: SNAPSHOT (2018)
  • FIGURE 66 LATIN AMERICA EXOSOME THERAPEUTIC MARKET: BY COUNTRY (2018)
  • FIGURE 67 LATIN AMERICA EXOSOME THERAPEUTIC MARKET: BY COUNTRY (2019 & 2026)
  • FIGURE 68 LATIN AMERICA EXOSOME THERAPEUTIC MARKET: BY COUNTRY (2018 & 2026)
  • FIGURE 69 LATIN AMERICA EXOSOME THERAPEUTIC MARKET: BY TYPE (2019-2026)
  • FIGURE 70 GLOBAL EXOSOME THERAPEUTIC MARKET: COMPANY SHARE 2018 (%)